XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

Xynomic Pharmaceuticals Holdings, Inc. (Nasdaq: XYN) is a clinical-stage biopharmaceutical company focused on oncology therapeutics that entered the public markets through a SPAC merger with CM Seven Star Acquisition Corp, which completed its initial public offering in 2018. Sponsored by CM Seven Star Acquisition Management LLC, the blank-check vehicle targeted the life sciences sector before closing its business combination with Xynomic and adopting the XYN ticker on Nasdaq. The company filed a 10-Q with the SEC on May 14, 2019, covering its first full quarterly reporting period as a post-merger public entity. Sign up at SpacDesk for full filing history, sponsor data, and analytics on XYN and the broader SPAC universe.